# Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

> **NCT00204659** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 30 (actual)

## Conditions studied

- Primary Gastric Diffuse-Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab + CHOP chemotherapy

## Key facts

- **NCT ID:** NCT00204659
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2008-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204659, "Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00204659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*